TAXUS LIBERTÉ REGISTRY COMPLETES FIRST ENROLLMENT

Boston Scientific has completed enrollment in the transitional phase of its OLYMPIA registry, designed to collect and analyze "real-world" clinical outcomes data for the company's next-generation Taxus Liberté paclitaxel-eluting stent system.

The OLYMPIA registry -- formerly known as the OLYMPIC registry -- plans to enroll more than 30,000 patients at more than 600 centers in the U.S., Europe and other international locations. The Taxus Liberté coronary stent system will be the next generation to Boston Scientific's Taxus Express2 paclitaxel-eluting coronary stent system.

The registry will enroll patients in five phases, corresponding to the commercial introduction of the Taxus Liberté system in different regions of the world. The first phase involved the enrollment of 500 patients from a limited number of international markets in which Boston Scientific launched the Taxus Liberté system in January. The final U.S. phases are expected to start enrollment in 2006.